Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel + carboplatin + adebrelimab as neoadjuvant and adjuvant therapy for resectable thymic carcinoma
ChiCTR2500107834Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Aug 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab, paclitaxel and carboplatin in thymic carcinoma (TC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Main pathological remission rate, Clinical downstaging rate (T and/or N downstaging) and 1 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
adebrelimabpaclitaxelcarboplatin
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2500107834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107834.